Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Core Scientific Inc (CORZ) Price & Performance

BioNTech SE - ADRTrade
Core Scientific IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Core Scientific Inc — how do they compare? BioNTech SE - ADR trades at $92.57 (market cap $23.31B), while Core Scientific Inc trades at $20.88 (market cap $6.35B). The key difference: BioNTech SE - ADR is far larger — about 3.7× Core Scientific Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXCORZ
Market Cap
$23.31B$6.35B
Sector
HealthTechnology
52-Week High
$119.34$29.16
52-Week Low
$83.89$13.55
Enterprise Value
$6.60B$8.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

Core Scientific Inc

CORZ trades at $21.30, up 9.57% in the last 24 hours, showing strong momentum despite a bearish technical signal. The stock faces fundamental challenges with a net income margin of -324.9% and negative EPS misses, but recent developments include a significant partnership with AMD for up to 2.5 gigawatts of data center capacity, potentially driving future revenue growth. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a consensus price target of $35.88.

The outlook for CORZ hinges on executing its AI infrastructure strategy, with the AMD deal offering substantial upside if successfully monetized. Key risks include persistent cash burn, competitive pressures, and reliance on long-term contracts. Investors should weigh the high growth potential against the current lack of profitability and volatile stock performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.

Read more on CORZ